Iceland founded Oculis Pharma has closed an oversubscribed $57 million Series C financing. Oculis said in a press release that the proceeds from the financing will accelerate the company’s strategy with the aim of delivering key goals in the near future to drive shareholder value and bring transformative therapies to patients. “The targeted milestones cover … Continue reading Oculis raises $57m Series C led by BVCF Management and Hyfinity Investments